New York-based genomic intelligence company Claryx has emerged from stealth with $3.5 million in pre-seed funding to expand its technology for detecting and tracing healthcare-associated infections.
The company has developed CloneLink, a genomic surveillance platform designed to identify hospital outbreaks as they occur, establish connections between individual infections and trace cases to their likely sources. Claryx said multiple health systems are currently using the technology.
CloneLink sequences the genomes of pathogens collected from confirmed patient infections and compares them to determine whether cases belong to the same transmission chain. The platform is intended to provide infection prevention teams with information about where interventions may be required and subsequently assess whether those measures have interrupted transmission.
Claryx can also compare patient infections with a digital representation of the hospital environment. This representation is developed using samples collected from air, water and surfaces, enabling the platform to identify environmental sources that could be associated with infections.
"We believe preventable infections are a solvable problem," Kurt Hackenberger, cofounder and CEO of Claryx, said in a statement. "Today we can tell a hospital where an infection came from. We're building toward a future where it never had to happen in the first place."
The financing will support continued development of Claryx's technology as the company works to strengthen infection surveillance and prevention capabilities within hospitals.
Healthcare-associated infections remain a significant issue despite improvements in prevalence. Published research indicates that one in 31 hospital patients had a healthcare-associated infection in 2015, compared with approximately one in 38 patients in 2023.
Healthcare organizations and public health agencies are increasingly deploying digital surveillance technologies to identify infectious disease threats. In 2025, the Oklahoma State Department of Health selected Conduent's Maven disease surveillance and outbreak management platform to support real-time detection, monitoring and reporting of infectious disease outbreaks and other public health threats.
Investment in genomic technologies has also continued across healthcare. Whole-genome sequencing company Inocras recently closed a $31 million Series B-3 round, bringing its total funding to approximately $100 million. Unlike Claryx's infection surveillance focus, Inocras applies genomic profiling and biomarker analysis primarily to cancer.
Click here for the original news story.
